SARTORIUS AG |
Market Closed -
Other stock markets
|
After market 03:59:59 pm | |||
| 185.6 EUR | +2.54% |
|
189 | +1.83% |
| 10:37am | Sartorius recovers 15 percent from annual low - Oddo recommendation | DP |
| 09:37am | SARTORIUS VORZUEGE : Oddo takes a positive view | ZD |
| Sales 2024 * | 3.54B 3.82B | Sales 2025 * | 3.94B 4.26B | Capitalization | 13.88B 15B |
|---|---|---|---|---|---|
| Net income 2024 * | 229M 247M | Net income 2025 * | 353M 381M | EV / Sales 2024 * | 5.04 x |
| Net Debt 2024 * | 3.95B 4.27B | Net Debt 2025 * | 3.7B 4B | EV / Sales 2025 * | 4.47 x |
| P/E ratio 2024 * |
61.2
x | P/E ratio 2025 * |
42.4
x | Employees | 14,614 |
| Yield 2024 * |
0.39% | Yield 2025 * |
0.5% | Free-Float | 35.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sartorius AG
More press releases
| 1 day | +3.20% | ||
| 1 week | +5.64% | ||
| Current month | +4.35% | ||
| 1 month | -2.50% | ||
| 3 months | -30.15% | ||
| 6 months | -26.73% | ||
| Current year | -29.36% |
1 week
166.20
187.40
1 month
166.20206.00
Current year
166.20290.00
1 year
166.20310.50
3 years
166.20834.00
5 years
138.50834.00
10 years
22.50834.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 99-04-30 | |
| Chief Tech/Sci/R&D Officer | 59 | 94-12-31 | |
Volker Niebel
COO | Chief Operating Officer | 67 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
BRD | Director/Board Member | 69 | 19-12-31 |
| Director/Board Member | 75 | 11-11-28 | |
| Director/Board Member | 58 | 17-04-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 414 M€ | +12.26% | - | |
| 0.00% | 36 M€ | +11.10% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-04 | 185.6 | +2.54% | 4 345 |
| 24-07-03 | 181 | +4.26% | 5,778 |
| 24-07-02 | 173.6 | +0.58% | 10,510 |
| 24-07-01 | 172.6 | -3.79% | 1,952 |
| 24-06-28 | 179.4 | +1.24% | 3,349 |
Delayed Quote Xetra, July 04, 2024 at 10:34 am EDT
More quotes
Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates in two segments: bioprocess solutions and lab products and services. The bioprocess solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, filter technology for clarification, among others. The lab Products and Services segment provides instruments, consumables, and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation, and membrane filter systems for sterility testing of parenteral.
Calendar
2024-07-19
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
220.9
EUR
Average target price
314.9
EUR
Spread / Average Target
+42.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.92% | 2.08B | |
| +22.96% | 1.94B | |
| -23.94% | 1.26B | |
| +18.47% | 1.22B | |
| -0.15% | 789M | |
| -37.32% | 720M | |
| -37.03% | 718M | |
| -29.95% | 587M | |
| +16.27% | 567M |
- Stock Market
- Equities
- SRT3 Stock
- SRT Stock
